List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 1.3. Preoperative medication and sedation for short-term procedures | No observations |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone, oxycodone |
PAHO Strategic Fund Medicine List | 1.1. Opioid analgesics | No observations |
Training CSamouge 2022 | 1.3 Preoperative medication and sedation for short-term procedures | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
List | Section | Observation |
---|---|---|
Bolivia | LINAME 2011 - 2013 | No observations |
List | Section | Observation |
---|---|---|
Ecuador | Essential Medicines List - Ecuador | No observations |
List | Section | Observation |
---|---|---|
Colombia | 2.1 Narcotic Analgesics | No observations |
List | Section | Observation |
---|---|---|
Cuba | 2.2 Analgésicos opioides |
Others observations: Liophylized for epidural and intrathecal injection |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone, oxycodone |
PAHO Strategic Fund Medicine List | 1.1. Opioid analgesics |
Others observations: Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times. |
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
List | Section | Observation |
---|---|---|
Peru | 2.2 Analgesic Opiates | No observations |
List | Section | Observation |
---|---|---|
Ecuador | Essential Medicines List - Ecuador | No observations |
List | Section | Observation |
---|---|---|
Colombia | 13.1 Narcotic Analgesics | No observations |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
List | Section | Observation |
---|---|---|
Ecuador | Essential Medicines List - Ecuador | No observations |
List | Section | Observation |
---|---|---|
Peru | 2.2 Analgesic Opiates | No observations |
List | Section | Observation |
---|---|---|
Peru | 2.2 Analgesic Opiates | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
List | Section | Observation |
---|---|---|
Bolivia | LINAME 2011 - 2013 | No observations |
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: Therapeutic alternatives: hydrormorphone and oxycodone |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 1.1. Opioid analgesics | No observations |
Chile | Essential and Prioritized Medications | No observations |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 1.1. Opioid analgesics |
Others observations: Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times. |
Peru | 2.2 Analgesic Opiates | No observations |
Chile | Essential and Prioritized Medications | No observations |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 1.1. Opioid analgesics |
Others observations: Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times. |
Chile | Essential and Prioritized Medications | No observations |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
Colombia | 13.1 Narcotic Analgesics | No observations |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics | No observations |